Distal Airway Stem Cells Seen to Block Fibrosis, Support Tissue Growth in PF Mouse Model

Distal Airway Stem Cells Seen to Block Fibrosis, Support Tissue Growth in PF Mouse Model

Distal airway stem cells (DASCs), which can differentiate into bronchioles and alveoli, were found to prevent fibrosis and support tissue regeneration in the lungs of mice.

These findings were reported in the study “Distal airway stem cells ameliorate bleomycin-induced pulmonary fibrosis in mice,” published in the journal Stem Cell Research & Therapy.

Idiopathic pulmonary fibrosis (IPF) is characterized by progressive lung tissue scaring and changes in cellular integrity, which lead to a loss of normal lung architecture. But its underlying mechanisms are still poorly understood.

Increasing evidence suggests that some populations of stem cells can promote tissue regeneration, and reverse the damage to lung tissue and vessels caused by IPF. DASCs, in particular, have shown a regenerative capacity after lung injury.

This population of stem cells appears to be highly activated upon damage, migrating to damaged areas where they undergo differentiation to replace the missing cells.

Researchers in China explored whether DASCs could reverse the effects of pulmonary fibrosis (PF) in a mouse model of the disease.

The team chemically induced PF by exposing mice to bleomycin. Seven days later, they analyzed the animals’ lungs and found that DASCs, which could be detected by the presence of KRT5 and P63 proteins, were located close to the bronchioles and alveolar space (where gas exchange occurs in the lungs).

Although the DASCs seemed to be contributing to the repair process, their low numbers low were not enough to overcome the extensive damage caused by bleomycin. So the researchers transplanted DASCs collected from healthy mice into the PF mice.

These additional cells effectively populated diseased tissue in the lungs of the PF mice, while in healthy lungs they had no detectable impact, suggesting that DASCs have a “special incorporation ability” in damaged tissue.

Further analysis revealed that the mice with transplanted DASCs had fewer lung tissue lesions compared to untreated PF mice. DASCs were also seen to effectively prevent tissue remodeling and collagen accumulation.

Overall, PF mice with a transplant of DASCs showed healthier post-injury pulmonary function and extended survival compared to untreated PF mice.

Supported by these findings, the team believes that “DASCs could be an ideal candidate stem cell for the therapy of pulmonary fibrosis.”

These cells can have a “lung-protective effect” due to their ability to contribute to “lung regeneration and prevention of pulmonary fibrosis development,” the researchers concluded.

Latest Posts
  • PROOF Esbriet pirfenidone
  • Weight loss risk
  • MN-001 patent Japan
  • Blade acquisition of Atxco, pulmonary fibrosis
Average Rating
0 out of 5 stars. 0 votes.
My Rating:


  1. Oh yes! When can I get started on it ?
    Hurry!! I need it now!!
    The two other approved meds made me very ill so am taking nothing and after 3 one half years I cannot do anything except sit or walk through the house. Roseann Richardson 82 years old and extremely active until about 6 months ago. :(.

    • Michael Edrington says:

      This seems rather positive compared to other developments in the treatment of IPF. I would be interested to sign “the right to try” paperwork as well.

  2. Larry says:

    Where do the donor stem cells come from and how are they implanted in the damaged area? Is there any risk of rejection?

  3. Steve Dragoo says:

    Sounds promising but lab induced IPF seems a lot different in mice than in humans. What is next for this one? Can we sign up somewhere?

  4. Sandie says:

    TY, Ms. Melao, for bringing this wonderful news to our attention! What is planned next? Plz know so so many are hoping & praying for its success. We needed this yesterday! Thank you, Researchers and team for all the hard work and effort! Plz never give up!

    • juliana says:

      Let us sign and do it first .We need it quick as possible due to this tormenting incurable disease. It will be of great help to the hopeless sufferers

  5. LouisPaul Epley says:

    Where and how do I volunteer for this program? I take no meds, 02 @2L,
    74 Year old male, Mayo Clinic lung biopsy confirms diagnosis. VAMC Healthcare patient, medium activity level, non smoker, no drugs. Thanks.

  6. Terri Soderberg says:

    Very interesting. Would love to get in on a trial test. I have lost 50% of my lungs. 69 till October. I am pretty active up to a point.

Leave a Comment

Your email address will not be published. Required fields are marked *